Flavoxate

Common Name

Flavoxate Description

A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefliness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] Structure

Synonyms

Value Source 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylateChEBI 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylateChEBI 2-Piperidinoethyl 3-methylflavone-8-carboxylateChEBI beta-Piperidinoethyl 3-methylflavone-8-carboxylateChEBI FlavoxatoChEBI FlavoxatumChEBI 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylic acidGenerator Flavoxic acidGenerator 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acidGenerator 2-Piperidinoethyl 3-methylflavone-8-carboxylic acidGenerator b-Piperidinoethyl 3-methylflavone-8-carboxylateGenerator b-Piperidinoethyl 3-methylflavone-8-carboxylic acidGenerator beta-Piperidinoethyl 3-methylflavone-8-carboxylic acidGenerator β-piperidinoethyl 3-methylflavone-8-carboxylateGenerator β-piperidinoethyl 3-methylflavone-8-carboxylic acidGenerator Flavoxate hciHMDB ortho Brand OF flavoxate hydrochlorideMeSH UronidMeSH Byk brand OF flavoxate hydrochlorideMeSH Hydrochloride, flavoxateMeSH Shire brand OF flavoxate hydrochlorideMeSH BladurilMeSH Flavoxate hydrochlorideMeSH Pierre fabre brand OF flavoxate hydrochlorideMeSH Recordati brand OF flavoxate hydrochlorideMeSH Cahill may roberts brand OF flavoxate hydrochlorideMeSH Hoechst brand OF flavoxate hydrochlorideMeSH Negma brand OF flavoxate hydrochlorideMeSH SpasuretMeSH UrispasMeSH

Chemical Formlia

C24H25NO4 Average Molecliar Weight

391.4596 Monoisotopic Molecliar Weight

391.178358293 IUPAC Name

2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate Traditional Name

flavoxate CAS Registry Number

15301-69-6 SMILES

CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1

InChI Identifier

InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3

InChI Key

SPIUTQOUKAMGCX-UHFFFAOYSA-N Chemical Taxonomy Description

This compound belongs to the class of chemical entities known as flavones. These are flavonoids with a structure based on the backbone of 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one). Kingdom

Chemical entities Super Class

Organic compounds Class

Phenylpropanoids and polyketides Sub Class

Flavonoids Direct Parent

Flavones Alternative Parents

  • Chromones
  • Pyranones and derivatives
  • Piperidines
  • Benzene and substituted derivatives
  • Heteroaromatic compounds
  • Trialkylamines
  • Carboxylic acid esters
  • Amino acids and derivatives
  • Oxacyclic compounds
  • Monocarboxylic acids and derivatives
  • Azacyclic compounds
  • Organopnictogen compounds
  • Organooxygen compounds
  • Organic oxides
  • Hydrocarbon derivatives
  • Substituents

  • Flavone
  • Chromone
  • Benzopyran
  • 1-benzopyran
  • Pyranone
  • Monocyclic benzene moiety
  • Piperidine
  • Pyran
  • Benzenoid
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Amino acid or derivatives
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Amine
  • Organopnictogen compound
  • Organic oxygen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Organic nitrogen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
  • Molecliar Framework

    Aromatic heteropolycyclic compounds External Descriptors

  • piperidines (CHEBI:5088 )
  • tertiary amino compound (CHEBI:5088 )
  • carboxylic ester (CHEBI:5088 )
  • flavones (CHEBI:5088 )
  • Ontology Status

    Expected but not Quantified Origin

  • Drug
  • Biofunction

  • Parasympatholytics
  • Application

  • Pharmaceutical
  • Cellliar locations

  • Membrane
  • Physical Properties State

    Solid Experimental Properties

    Property Value Reference Melting PointNot AvailableNot Available Boiling PointNot AvailableNot Available Water Solubility1.54e-02 g/LNot Available LogP4.4Not Available

    Predicted Properties

    Property Value Source Water Solubility0.015 mg/mLALOGPS logP3.65ALOGPS logP4.24ChemAxon logS-4.4ALOGPS pKa (Strongest Basic)7.29ChemAxon Physiological Charge1ChemAxon Hydrogen Acceptor Count4ChemAxon Hydrogen Donor Count0ChemAxon Polar Surface Area55.84 Å2ChemAxon Rotatable Bond Count6ChemAxon Refractivity113.51 m3·mol-1ChemAxon Polarizability43.39 Å3ChemAxon Number of Rings4ChemAxon Bioavailability1ChemAxon Rlie of FiveYesChemAxon Ghose FilterYesChemAxon Vebers RlieYesChemAxon MDDR-like RlieYesChemAxon

    Spectra Spectra

    Spectrum Type Description Splash Key Predicted LC-MS/MS

    Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available Predicted LC-MS/MS

    Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available Predicted LC-MS/MS

    Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available Predicted LC-MS/MS

    Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available Predicted LC-MS/MS

    Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available Predicted LC-MS/MS

    Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available

    Biological Properties Cellliar Locations

  • Membrane
  • Biofluid Locations

  • Blood
  • Urine
  • Tissue Location

    Not Available Pathways

    Not Available Normal Concentrations

    Biofluid Status Value Age Sex Condition Reference Details BloodExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01148

  • 21059682
  • details UrineExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01148

  • 21059682
  • details

    Abnormal Concentrations

    Not Available Associated Disorders and Diseases Disease References

    None Associated OMIM IDs

    None External Links DrugBank ID

    DB01148 DrugBank Metabolite ID

    Not Available Phenol Explorer Compound ID

    Not Available Phenol Explorer Metabolite ID

    Not Available FoodDB ID

    Not Available KNApSAcK ID

    Not Available Chemspider ID

    3237 KEGG Compound ID

    C07809 BioCyc ID

    Not Available BiGG ID

    Not Available Wikipedia Link

    Flavoxate NuGOwiki Link

    HMDB15279 Metagene Link

    HMDB15279 METLIN ID

    Not Available PubChem Compound

    3354 PDB ID

    Not Available ChEBI ID

    5088

    Product: HDAOS

    References Synthesis Reference Not Available Material Safety Data Sheet (MSDS) Not Available General References Not Available

    Enzymes

    General function:
    Involved in G-protein coupled receptor protein signaling pathway
    Specific function:
    The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover
    Gene Name:
    CHRM1
    Uniprot ID:
    P11229
    Molecular weight:
    51420.4
    References
    1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
    2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
    3. Abbiati GA, Ceserani R, Nardi D, Pietra C, Testa R: Receptor binding studies of the flavone, REC 15/2053, and other bladder spasmolytics. Pharm Res. 1988 Jul;5(7):430-3. [PubMed:3247311 ]
    General function:
    Involved in G-protein coupled receptor protein signaling pathway
    Specific function:
    The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition
    Gene Name:
    CHRM2
    Uniprot ID:
    P08172
    Molecular weight:
    51714.6
    References
    1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
    2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
    3. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
    4. Uckert S, Stief CG, Odenthal KP, Truss MC, Lietz B, Jonas U: Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. Arzneimittelforschung. 2000 May;50(5):456-60. [PubMed:10858873 ]
    5. Abbiati GA, Ceserani R, Nardi D, Pietra C, Testa R: Receptor binding studies of the flavone, REC 15/2053, and other bladder spasmolytics. Pharm Res. 1988 Jul;5(7):430-3. [PubMed:3247311 ]

    PMID: 19818703